This observational study compares advanced immunochemotherapy with classical immunochemotherapy in patients with relapsed or refractory high grade B cell lymphoma. The advanced group includes CAR-T therapy, bispecific antibodies and antibody-drug conjugates, while the classical group includes proteasome inhibitors, immune modulatory drugs and monoclonal antibodies. Survival outcomes and treatment-related safety are assessed from laboratory findings and electronic medical records in adults aged 19 to 74 diagnosed after January 2015 with diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, high grade B cell lymphoma or Burkitt lymphoma.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Adults aged 19 to 74 years. * Diagnosed with any of the following after January 2015: diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, or Burkitt lymphoma * Patients who have received immunochemotherapy as treatment for relapsed/refractory lymphoma Exclusion Criteria: * Patients who have progressed to acute leukemia * Patients who developed solid tumor during treatment * Patients with active infectious status (acute pneumonia, viral infection, active hepatitis B state, or active pulmonary tuberculosis etc.)